BMO Capital analyst Evan Seigerman lowered the firm’s price target on Mirati Therapeutics to $31 from $40 and keeps a Market Perform rating on the shares. The company’s Q2 results were a “tale of mixed emotions”, with CEO departure and $250M secondary countered by decent Krazati revenue growth, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRTX:
- Mirati Therapeutics price target raised to $83 from $77 at Stifel
- Mirati Therapeutics assumed with an Overweight at Piper Sandler
- Mirati Therapeutics upgraded to Buy from Neutral at B. Riley
- Mirati Therapeutics 9.7M share Spot Secondary priced at $27.80
- Mirati Therapeutics price target raised to $62 from $56 at Oppenheimer